¡i¥xÆW¥úµØ¹q¤l³ø¡jÅý§A²`¤J¤F¸Ñ¥xÆWªÀ·|¡A­Ý¨ã°ê»ÚÆ[»P¥»¤g«äºû²`«×³ø¾É¡A¬°§A§e²{¥t¤@ºØ¾\Ū¥xÆWªº¤è¦¡¡C ¡iªF¼g¦èŪ¹q¤l³ø¡jºK¿ý¡m¦nŪ©P³ø¡nºë±m¸ÜÃD¡A¥H±À¼s¾\Ū»P¼g§@¬°®Ö¤ß¤º®e¡AÅý±z´x´¤¨C©P³Ì·s¤º®e¡I
¡¹ µLªk¥¿±`ÂsÄý¤º®e¡A½Ð«ö³o¸Ì½u¤W¾\Ū
·s»D  °·±d  udn³¡¸¨®æ  
2023/06/29 ²Ä502´Á  |  ­q¾\¡þ°h­q  |  ¬Ý¾ú¥v³ø¥÷  |  ¥_¬ü´¼Åvºô¯¸
 
 
 
 
±M§QµûªR UPC 2023/06/01¥¿¦¡±Ò¥Î ¦A½ÍOpt-out¤ÎProtective Letter
   
ªk³W¶D³^ ­G»Ä§í¨îÃĪ«¤Æ¾Çºc³yªºÅã¦Ó©ö¨£©Ê (¤T)¡GAltana Pharma AG v. Teva Pharmaceuticals USA, Inc. (Fed. Cir.2009)
   
²`¤J³ø¾É ªF«n¨È²£¯à±U°_¡G¶V«n±N¦¨¬°¥t¤@­Ó¤¤°ê¼sªF¡H
   
¬ãµo³Ð·s ¡m¼Æ¦ìÂ૬±M¿è¡n-2 ¥ø·~¼Æ¦ìÂ૬¸gÅç¤À¨É¡G¸s³Ð¥ú¹q¤Î¤¤¥ú¹q´¼¯àª«¬y
   
´¼°]ºÞ²z ¡mIP¤pÃã¨å¡n±M§QÅv½èÅv
   
 
UPC 2023/06/01¥¿¦¡±Ò¥Î ¦A½ÍOpt-out¤ÎProtective Letter
¶ÀÄõ¶{¡þ¥_¬ü´¼Åv¡@´¼Åvªk³W¬ã¨s²Õ
¼Ú¬w±M§Q·~¬É2023¦~ªº³o­Ó6¤ë¡A¼ö¾x¯É§e¡AÂǼڬw³æ¤@±M§Qªk°|¡]Unified Patent Court¡A²ºÙUPC¡^¥¿¦¡±Ò¥Îªº¾÷·|¡A¦A½Í¤@¤UOpt-out¤ÎProtective Letter¹B§@¾÷¨î¡C

¡m¼Ú¬w³æ¤@±M§Qªk°|¨óij¡n¡]Agreement on a Unified Patent Court¡A²ºÙUPCA¡^2023¦~6¤ë1¤é¥¿¦¡¥Í®Ä¡A¼Ú¬w³æ¤@±M§Q¡]Unitary Patent¡A²ºÙUP¡^¤Î¼Ú¬w³æ¤@±M§Qªk°|¡]Unified Patent Court¡A²ºÙUPC¡^¦P¨B±Ò¥Î[1]¡C¨ä¤¤UPC³oÀY¡A¤@¦p¥ý«e¹w´Á¡A­^°ê­Û´°¥X¯Ê«áªºUPC²Ä¤T®y¤¤¥¡¤À°|½T©w¸¨¸}¸q¤j§Q¦ÌÄõ[2]¡AUPCA¥Í®Ä«eªº¤é¥X´Á¶¡´é²{¤j¶qOpt-out¥Ó½Ð»Ý¨D[3]¡A¦P®É¦bUPC¥¿¦¡¶}ªù¹B§@«á¡AªG¯u¤]¦³¤£¤Ö¤H·m¦b²Ä¤@®É¶¡»¼ª¬[4]¡A¼Ú¬w±M§Q·~¬É2023¦~ªº³o­Ó6¤ë«Ü¬O¼ö¾x¡C¤£¹L§Y¨Ï¤£·Ç³Æ¥D°Ê¿³³^¡A«Øij¤´À³¤F¸ÑUPC¦pOpt-out¡BProtective Letter¤§Ãþªº¨¾¿m¾÷¨î¡C

Opt-outµn¿ý«á¤´¥i¯à¦³UPCµ{§Ç

UPCA¥Í®Ä«e¡A³\¦h¼Ú¬w¨Æ°È©ÒªºÁ¿®y¤Î»¡©«³£±j½Õ¨Ã¤O±ÀOpt-out¡G¶Ç²Î¼Ú¬w±M§Q¡]Classic European Patent¡A¥H¤U²ºÙ¶Ç²ÎEP¡^µn¿ýOpt-out¡A¥i±Æ°£UPC§@UPCA Article 32.1³W©w¶D³^ºÞÁÒªk°|ªº¥i¯à¡AÁקK¦b¼Ú¬w¦h°êªº±M§QÅv³Q¤@¦¸KO¡C©ó¬O¡A²³¦h¶Ç²ÎEP©Ò¦³Åv¤H­·­·¤õ¤õ·m¦b¤é¥X´Á¶¡´£¥æOpt-out¥Ó½Ð¡A¤£¹L«Ü¦h¤H³£©¿²¤¤F¤@ÂI¡A¤@¶Ç²ÎEP§Y¨Ï§¹¦¨Opt-outµn¿ý¡A¸Ó¶Ç²ÎEP¤§«áÁÙ¬O¥i¯à¦³UPCµ{§Ç­n¶]¡C

¦bUPC°w¹ï¯S©w¶Ç²ÎEPµn¿ýOpt-out¡BÁn©ú¬ÛÃö¶D³^¤£¥HUPC§@ºÞÁÒªk°|¡Aªº½T·|¬°¸Ó¶Ç²ÎEP¦bUPC¬[°_«OÅ@³Ê¡A¦ý³o§â«OÅ@³ÊµLªk¦Û°Ê¼u¶}²Ä¤T¤èªº±M§QºM¾P¡]Revocation¡^§ðÀ»¡C®Ú¾ÚUPCµ{§Ç³W«h¡]Rules of Procedure of the Unified Patent Court¡^Rule 48¡ASection 2³W½dªº±M§QºM¾P¶D³^µ{§Ç¡A­ã¥ÎSection 1«IÅv¶D³^µ{§ÇRules 19-21°£Rule 19.4¤§¥~ªº©Ò¦³±ø¤å¡A¦Ó¨ä¤¤ªºRule 19.1(a)³W©w¡A¦b­ì§iµo°Ê§ðÀ»«á¡A³Q§i¥i©ó1­Ó¤ë¤º´£ªì¨B²§Ä³¡]preliminary objection¡^¡A¥Ó©ú¨tª§±M§Q¾A¥ÎRule 5ªºOpt-out³W©w¡BUPC«D¾A®æºÞÁÒªk°|¡C

¹ê¨Æ¤W¡AOpt-out¥Ó½Ð°e¥óµLªk´£¥æ©Ò¦³Åv¤H¤å¥ó¸ê®Æ¡AUPC³B²zOpt-out¥Ó½Ð®É¤]¤£·|¥ý®Ö¹ê¥Ó½Ð¤H¸ê®æ[5]¡A¦]¦¹¡A§Y¨Ï¦bUPC´N¤@¶Ç²ÎEPµn¿ýOpt-out«á¡A²Ä¤T¤è¤´¥i¹ï¸Ó¶Ç²ÎEP´£¥X±M§QºM¾P¶D³^¡C·í­±¹ï³oºØ±¡ªp¡A¶Ç²ÎEP±M§Q©Ò¦³Åv¤H»Ý¨Ìªk¦^À³¡B´£¥Xªì¨B²§Ä³¡A¤~¯à¥OUPC½T»{¹ï¸Ó¶Ç²ÎEPªº±M§QºM¾P¶D³^¤£¨ãºÞÁÒÅv¡C

´«¨¥¤§¡AOpt-outµn¿ý«á¡A¤£¬O´N¦¹»PUPCµ{§Çµ´½t¡A§Y¨Ï¨u¨£¡A¶Ç²ÎEP©Ò¦³Åv¤HÁÙ¬O¥i¯à¸I¤WUPC±M§QºM¾P¶D³^¡A©y¥ý°µ¦n¤ß²z·Ç³Æ¡A²¦³º¡A¤@­Ó¤ëªº¤ÏÀ³®É¶¡¤£ºâ¯S§O¥R¸Î¡C

ªì¨B¸T¨î¥O¨¾¿m´î¨a¤u¨ã¡GProtective Letter

¹ïUPC¶D³^§Ù·V®£Äߪº¡A°£¤F¾á¤ß¼Ú·ù¦h°ê±M§QÅv¤@¦¸¹Î·Àªº¶Ç²ÎEP©Ò¦³Åv¤H¡AÁÙ¥]¬A³\¦h¦³¼Ú·ù·~°È¡B¾á¤ß¤@¦¸¦b¼Ú·ù¦h°ê³Q»{©w«IÅvªº¤j¤p¥ø·~¡A¥ý«e¶Ç¨¥«D±M§Q¹ê¬I¹êÅé¡]non-practicing entity¡A²ºÙNPE¡^¤w¬Û·ÇUPC·Q¤j®i¨­¤â¡A¤×¨ä¤Þ¤H¼~¼{¡C¤£¹L­n¬O¤wª¾¦³³Q«ü±±«I®`¯S©w±M§Q±M§QÅvªº­·ÀI¡A¥i¯àÀ³¶}©l¬ã¨sUPCªì¨B¸T¨î¥O¡]preliminary injunction¡A²ºÙPI¡^¡B«OÅ@ª¬¡]protective letter¡A²ºÙPL¡^¡C

¤¤¼Ú®É¶¡2023¦~6¤ë1¤W¤È9®É°_¡A¶Ç²ÎEP¤ÎUP©Ò¦³Åv¤H¥iÂÇUPC¶D³^µ{§Ç¦b¼Ú·ù17°ê¦æ¨Ï±M§QÅv¡A¤×¨ä­È±oª`·Nªº¬O¡A¨ÌUPCµ{§Ç³W«hRule 212¡AUPC¤ð¶·Å¥¨ú³Q§i»¡ªk¡A§Y¥i¤U¹Fªì¨B¸T¨î¥O[6]¡A©Ò¥H©Î³\¦³³Q±±«IÅv¤H¬O¦bªk°|ªì¨B¸T¨î¥O°e¹F¡B¶}©l°õ¦æªº·í¤U¤~Ååı¤j¨Æ¤£§®¡A¾¨ºÞ¦¹®É¤´¦³¾÷·|¦b30¤Ñ¤º½Ð¨Dªk©x­«·s¦Ò¼{¡A¦ý»P¨ä³Q°Ê¦^À³¡A§Q¥ÎUPC«OÅ@ª¬¹w¥[¨¾½d¡A¤£¶È¯àÁקKªk©x³æ¾Ì¹ï³y¤@­±¤§µüµo¥¬ªì¨B¸T¨î¥O¡A¨Ã¥iª§¨ú§ó¦h®É¶¡ÂX®i§ÜÅG½×­z¡C

¨ÌUPCµ{§Ç³W«hRule 207³W©w¡A¥ô¦ó¦³Åv©óUPC¨ãª¬°_¶DªÌ¡A­Y¹w§P¦³¥i¯à³Qµø¬°ªì¨B¸T¨î¥O¤§Ãþªº¼È®É±¹¬I³Q§i¤è¡A¬Ò¥i¥ý´£UPC«OÅ@ª¬¡A³¯©ú¥i¯àªº°_¶D­ì§i¡]­Y¦³©ú½Tªº±M§QÃҮѸ¹¡A¥ç¥i¥[¥H´£¥Ü¡^¤Î³W©w°ò¥»¸ê®Æ¡A¥H¦U¶µ¨Æ¹ê¤Î¬ÛÃöÃÒ¾Ú»¡©ú¦ó¥H¨ä²£«~¥¼«IÅv¡B¼Ðªº±M§Q¬°¤°»òµL®Ä¡B¬°¦ó¤£©y­ãµoªì¨B¸T¨î¥O¤§Ãþ¡C¦p¦¹¤@¨Ó¡A®Ú¾ÚRule 209.2(d)¡AUPCªk©x¹J¦³ªì¨B¸T¨î¥O¥Ó½Ð¡A§Y¶·¬d¬Ý¬O§_¦³³Q±±«IÅv¤è¤w¥ý´£¥æ«OÅ@ª¬¡A­Y¦³¡A¨ÃÀ³¦Ò¼{¬O§_ÁܽÐÂù¤è·í¨Æ¤H¥X®uÅ¥¨úÂù¤è»¡ªk¡C

»¼¥æUPC«OÅ@ª¬»Ýú200¼Ú¤¸³W¶O¡A¥i¦bUPC¦s¨÷6­Ó¤ë¡A°£«D«áÄò¦³¤H»¼¥ó½Ð¨DUPCµo¥¬ªì¨B¸T¨î¥O¡A¥~¬ÉµL±q¨Æ¥ý±oª¾¦³¦¹UPC«OÅ@ª¬ªº¦s¦b¡C­Y´Á¶¡µL¤H¥Ó½Ðµo¥¬¸T¨î¥O¡A¦ý§PÂ_­·ÀI¥¼¸Ñ°£¡A¥i¦b6­Ó¤ë´Áº¡«e¥[ú100¼Ú¤¸¡A©µªø¦s¨÷®É¶¡¦A6­Ó¤ë¡C¥u¤£¹L¦³¼Ú¬w¨Æ°È©Ò´£¿ô¡A¾¨ºÞUPC¦³¦¹¾÷¨î¡A¦pªG«OÅ@ª¬¥¼¯à´£¥X¦³¤OªºÃÒ¾Ú½×ÂI¡A¶TµM´£¥X¡A¤]¥i¯à±a¨Ó¤Ï®ÄªG¡]ªk©x¥i¯à·Q¡A³Q§i¤è¯à´£¥XªºÃÒ¾Ú½×ÂI´N¥u¦³³oµ{«×¡A¨º·íµM¸Ó­ãµoªì¨B¸T¨î¥O¡^¡C[7]

¡i¥»¤å¥¼§¹¡A§¹¾ã¤º®e½Ð¨£¡m¥_¬ü´¼Åv³ø¡n335´Á¡GUPC 2023/06/01¥¿¦¡±Ò¥Î ¦A½ÍOpt-out¤ÎProtective Letter¡j

¡°¦p±ýÂà¸ü¥»¤å¡A½Ð»P¥_¬ü´¼Åv³øÁpµ¸

³Æµù¡G

1.The Unified Patent Court opens its doors!¡A½Ð¨£https://www.unified-patent-court.org/en/news/unified-patent-court-opens-its-doors¡C

2.½Ð¨£¸q¤j§Q¥~¥æ¨Æ°Èº[¥qªk³¡©xºô2023¦~5¤ë18¤é·s»D½Z¡Ahttps://www.esteri.it/en/sala_stampa/archivionotizie/comunicati/2023/05/tribunale-unico-dei-brevetti-italia-otterra-sezione-distaccata-per-milano/¡C2020¦~ªì­^°êºM¦^UPCA§å­ã¤å®Ñ¡A¦P¦~9¤ë¸q¤j§Q§Y¿ï©w¥H¦ÌÄõ¬°¾ÚÂI¡A¿n·¥ª§¨ú»¼¸É­Û´°ªÅ¥XªºUPC¤@¼f¤¤¥¡¤À°Ïªk°|¦ì¸m¡A¦ý¸q¤j§Q©xºô·s»D½Z¶È´£¨ì¡AUPC¦ÌÄõ¤¤¥¡¤À°Ïªk°|±N­t³d»P¸Ó°êEntrepreneurial System¬ÛÃö»â°ì®×¥ó¡A¨s³º²[»\­þ¨Ç§Þ³N»â°ì®×¥ó¡A¤´¦³«Ý¥¼¨ÓÂç²M¡A¥B¦]»Ý¸gUPCA¦¨­û°ê³q¹L­×­qUPCA¡AUPC¦ÌÄõ¤¤¥¡¤À°Ïªk°|¶}©l¹B§@ªº®É¶¡¥¼©w¡A­ì¥æ¥ÑUPC­Û´°¤¤¥¡¤À°Ïªk°|¼f²zªº°ê»Ú±M§Q¤ÀÃþAÃþ¤ÎCÃþ®×¥ó¡]§Y¤Æ¾Ç¡B§Mª÷¥H¤Î¤HÃþ¥Í¬¡¥²»Ý«~¡^¡A¤§«e¤w«Å¥¬¥ý¥æUPCªk°ê¤Ú¾¤¤Î¼w°ê¼}¥§¶Â¤¤¥¡¤À°Ïªk°|±µ¤â¡A¸Ô±¡½Ð°ÑUPC©xºô2023¦~5¤ë16¤é·s»D½Z¡Ahttps://www.unified-patent-court.org/en/news/decision-provisional-distribution-actions-related-patents-ipc-sections-and-c-pending-central¡C

3.½Ð°Ñ¦ÒUPC©xºô·s»D½Z¡Ghttps://www.unified-patent-court.org/en/news¡CUPC°e¥ó®×ºÞ¥­¥xCMS¦]®ü¶qOpt-out°e¥ó¬d¸ß§@·~³t«×½wºC¡A©x¤è¥ý¦b2023¦~5¤ë17¤é¹w§i¥i¯à­­¨î³¡¤ÀÃþ«¬°e¥ó¬y¶q¡A23¤éÃÒ¹ê¶}©l­­¨î³¡¤À»P¥~³¡¨Ï¥ÎªÌ§ì¨ú°T®§¬ÛÃöªº«D­«­nCMS¥\¯à¡A¨Ã¼È®ÉÃö³¬©Ò¦³Public API¡A¦P®É©ó25¤é´£¿ô¶È©óUPC¤½§i±¡ªp¤U¥i´£¥æ¯È¥»¤å¥ó¡C

4.Update on the performance of the CMS¡A½Ð¨£https://www.unified-patent-court.org/en/news/update-performance-cms¡CUPCÁö¥¼ÄÀ¥X¥¿¦¡²Î­p¼Æ¾Ú¡A¦ý¤¤¼Ú®É¶¡2023¦~6¤ë1¤W¤È9®É¨j¸g±Ò¥Î¡AUPC±Û§Y¦A¬°¸Ó°|°e¥ó®×ºÞ¨t²ÎCMS¤ÏÀ³³t«×¿ð½wµo¥¬¤½§i¡A¨äµ{§Ç»Ý¨D¥iÆ[¡A¥Ñ¦¹¥i¨£¤@´³¡C

5.¥i°Ñ¦ÒUPC FAQ½s¸¹4.6»¡©ú¡A½Ð¨£https://www.unified-patent-court.org/en/faq/opt-out-0#faqs¡C

6.­Y©ì©µµo¥¬¸T¨î¥O¥i¯à³y¦¨­ì§iµL¥HÀ±¸Éªº·l¥¢©Î³Q§i¦³·ÀÃÒ¤§¸·¡A¥i¯à±j¤ÆUPCµo¥¬³æ¤è¸T¨î¥Oªº¶É¦V¡A¦ý«DUPCµ{§Ç³W«hRule 212³W½dªº¥ý¨M­n¥ó¡C®Ú¾Ú³ø¾É¡A¦³¼w°ê¡B²üÄõÄyUPCªk©x¹ªÀy¨Ï¥Î³oÃþ¼È®É±¹¬I¡A¤×¨ä¹J¦³®É¶¡«æ­¢©Êªº®×¥ó¡A¥¼Å¥¨ú³Q§i»¡µü§YºB´n­ãµoªì¨B¸T¨î¥Oªº¾÷²v¤£§C¡C¥i°Ñ¦ÒUPC Protective Brief ¡V why implementers should consider it¡A½Ð¨£https://www.bardehle.com/en/ip-news-knowledge/ip-news/news-detail/upc-protective-brief-why-implementers-should-consider-it¡C

7.Protective letters under the UPC system¡A½Ð¨£https://www.taylorwessing.com/en/insights-and-events/insights/2023/05/protective-letters-under-the-upc-system¡C

 
­G»Ä§í¨îÃĪ«¤Æ¾Çºc³yªºÅã¦Ó©ö¨£©Ê (¤T)¡GAltana Pharma AG v. Teva Pharmaceuticals USA, Inc. (Fed. Cir.2009)
µ§ªÌ¥H¤T½g¨t¦C¤å³¹¤è¦¡¸Ô²Ó¤¶²Ð­G»Ä§í¨îÃĪ«¤Æ¾Çºc³yªºÅã¦Ó©ö¨£©Ê¡A¥»¤å¬°²Ä¤T½g¡GAltana Pharma AG v. Teva Pharmaceuticals USA, Inc. (Fed. Cir.2009).[1]¡C(²Ä¤@½g½Ð¨£¥_¬ü´¼Åv³ø333´Á¡m­G»Ä§í¨îÃĪ«¤Æ¾Çºc³yªºÅã¦Ó©ö¨£©Ê (¤@)¡GYamanouchi Pharm. Co. v. Danbury Pharmacal,Inc. (Fed. Cir. 2000). ¡n¡B²Ä¤G½g½Ð¨£¡m¥_¬ü´¼Åv³ø334´Á¡m­G»Ä§í¨îÃĪ«¤Æ¾Çºc³yªºÅã¦Ó©ö¨£©Ê (¤G)¡GEisai Co. Ltd. v. Dr. Reddy's Laboratories, Ltd. (Fed. Cir. 2008).¡n¡^¡C

®×¥ó­I´º

¥»®×³Q§i±è¥Ë (Teva)¡B¤Ó¶§ (Sun)¡B¤ÎKudco ¾Ç¦WÃļt (¥H¤U¦XºÙ±è¥Ë¾Ç¦WÃļt) ¦]¬°¦V¬ü°ê­¹«~ÃĪ«ºÞ²z§½ (FDA) ´£¥X¤F­G»Ä§í¨îÃĪ«Protonix —û (¦¨¤À¬°Ìñ¦«©ÔÐü¡Apantoprazole) ªº¾Ç¦WÃij\¥i¤§Â²©ö·sÃĤW¥«µ{§Ç (ANDA) ¡C­ì§iªüº¸¶ð¯Ç (Altana Pharma) Ãļt©ó¬O¦V¬ü°ê¯Ã¿A¦è¦{ (the District of New Jersey) ªºÁp¨¹¦a¤èªk°|´£¥X±M§Q«IÅv¶D³^¡A¥D±i³Q§i±è¥Ë¾Ç¦WÃļt«I®`¤F¨tª§±M§Q¥Ó½Ð±M§Q½d³ò¤¤ªºÃĪ«ºc³y¡A¨Ã¦V¦a¤èªk°|Án½Ðµo§Gªì¨B¸T¨î¥O (preliminary injunction) ¡C³Q§i±è¥Ë¾Ç¦WÃļt«h¥D±i­ì§iªüº¸¶ð¯ÇÃļtªº¨tª§±M§Q¥Ó½Ð±M§Q½d³ò¤¤ªºÃĪ«ºc³y¦]Åã¦Ó©ö¨£©Ê¦ÓµL®Ä¡A¦a¤èªk°|±Ä¯Ç¤F³Q§i±è¥Ë¾Ç¦WÃļt©Ò¥D±iªºÅã¦Ó©ö¨£©Ê§ÜÅG¡A¦]¦¹¡A§_­ãªì¨B¸T¨î¥Oªºµo§G¡C­ì§iªüº¸¶ð¯ÇÃļt¤£ªA¦a¤èªk°|ªº»{©w¡A©Ò¥H´£¥X¤W¶D¡C

­G»Ä¤Àªc¤Î­G»Ä§í¨îÃĪ«

­G³¡¦ì©ó¤HÅ骺¸¡µÄ¤¤¡A¨ä¥~¼h¬°­G¾À¡A­G¾À¤¤¦³³\¦hªº­G¾À²Ó­M (parietal cell) ¡A¦Ó­G¾À²Ó­M¯àÂǥѨä¤Wªº²BÂ÷¤lÀ°®ú (Proton pump) ±N²BÂ÷¤l¤Àªc¦Ü­G³¡¤¤¡A¨Ï­G³¡§e²{»Ä©Êª¬ºA¥H§Q­¹ª«ªº®ø¤Æ¡C·í­G¾À²Ó­Mªº²BÂ÷¤lÀ°®ú¤Àªc¤Ó¹L©ô²±®É¡A´N·|³y¦¨­G­¹¹D°f¬y¡B­G¼ìºÅ¤Î¤Q¤G«ü¸z¼ìºÅµ¥¯gª¬¡C

²BÂ÷¤lÀ°®ú§í¨î¾¯ (Proton pump inhibitors) ¬O¤@ºØ¯à°÷ÂǥѪ½±µ§í¨î­G¾À²Ó­M¤Wªº²BÂ÷¤lÀ°®ú¡A¨äÂǥѴî¤Ö²BÂ÷¤l¤Àªc¦Ü­G³¡¨Ó¹F¨ìªvÀø­G»Ä¹L¦h©Ò³y¦¨ªº°f¬y¤Î¼ìºÅ¯gª¬¡CÁ{§É¤W¨Ï¥Îªº²BÂ÷¤lÀ°®ú§í¨î¾¯¡A¨Ò¦p¡G¶ø¬ü©ÔÐü (omeprazole¡A¹Ï1) ¡B¹p¨©©ÔÐü (rabeprazole¡A¹Ï2) ¡BÄõ¯Á©ÔÐü (lansoprazole¡A¹Ï3) ¡B¤ÎÌñ¦«©ÔÐü (¹Ï4)[2]¡C

¥Ñ¹Ï1¦Ü¹Ï4ªº¶ø¬ü©ÔÐü¡B¹p¨©©ÔÐü¡BÄõ¯Á©ÔÐü¡B¤ÎÌñ¦«©ÔÐüºc³y¹Ï¤¤¡A¥iª¾²BÂ÷¤lÀ°®ú§í¨î¾¯¨ã¦³¦@³q©Êªººc³y (¹Ï5)¡A¦¹ºc³yºÙ¬°Br Ændstr Ém®Ö¤ß¤Æ¾Çºc³y¡CBr Ændstr Ém®Ö¤ß¤Æ¾Çºc³y¥Ñ¹Ï5¥ª¦Ü¥k¤À§O¬O¥Ñ­f¦}«}Ðü (benzimidazole) ¡B¨ÈÁDñQ°ò¥Ò°ò (sulfinylmethyl) ¡B¤Î–²Ôr (pyridine) ¤T³¡¤À©Òºc¦¨¡CÂǥѦbBr Ændstr Ém®Ö¤ß¤Æ¾Çºc³y¤W§@¤£¦Pªº¨ú¥N°ò­×¹¢¡A¥i¥H±o¨ì¤£¦Pªº²BÂ÷¤lÀ°®ú§í¨î¾¯¡C

¹Ï1 ¶ø¬ü©ÔÐüªº¤Æ¾Çºc³y

¹Ï¤ù¨Ó·½¡GGeorge Sachs µ¥¤H¤§½×¤åµoªí[3]¡@

¡i¥»¤å¥¼§¹¡A§¹¾ã¤º®e½Ð¨£¡m¥_¬ü´¼Åv³ø¡n335´Á¡G­G»Ä§í¨îÃĪ«¤Æ¾Çºc³yªºÅã¦Ó©ö¨£©Ê (¤T)¡GAltana Pharma AG v. Teva Pharmaceuticals USA, Inc. (Fed. Cir.2009)¡j

¡°¦p±ýÂà¸ü¥»¤å¡A½Ð»P¥_¬ü´¼Åv³øÁpµ¸

 
ªF«n¨È²£¯à±U°_¡G¶V«n±N¦¨¬°¥t¤@­Ó¤¤°ê¼sªF¡H
§dºÑ®Z¢¬¥_¬ü´¼Åv³ø¡@½s¿è³¡
¥þ²y´º®ðªº´_µd¡A¥þ²y¤j¼t¯É¯É¬Û¤¤¨È¬w¨ÑÀ³Ã쥫³õªº¦h¤¸­I´º¡A±N²£½u³]¸m©ó¨È¬wªº±¡§Î¤é¯q­Ñ¼W¡CKPMG¡B¤Ó¥­¬v¬Ö¦a¸gÀÙ²z¨Æ·|¡]PBEC¡^¤Î¿D¬w»X¯Ç³\¤j¾Ç°¨¨Ó¦è¨È¤À®Õ¡]Monash University Malaysia¡^¤é«e¦@¦Pµo¥¬¡m¨È¤Ó¦a°Ï¥þ²y±ÄÁʸѱK¡n¡AÅã¥Ü¤j³¡¤Àªº²£¯à¬y°Êµo¥Í¦b¨È¬w¡A¨ä¤¤55%¶°¤¤¦bªF«n¨È¤Î«n¨È¡CKPMG¦w«J«Ø·~±M·~µ¦²¤ªø¦À¥@´Ü»{¬°¡A¥ø·~¾E²¾²£¦a¦ÜªF«n¨È¦a°Ï¡A³Ì¥D­nªº­ì¦]¬O­nÁקK¹L«×¥õ¿à³æ¤@¥«³õ»s³y¡A¦Ó¶V«n¬O³oªi²£¦a²¾Âà³Ì¤jªº±µ¦¬°ê®a¡Aµo®i³t«×¶W¥G¹w´Á¡A³ô¤ñ¬O¤Q¦~«eªº¼sªF½ª©¡K¡K

¡m¨È¤Ó¦a°Ï¥þ²y±ÄÁʸѱK¡n³ø§i¥D­n¨ü³X¹ï¶H¬O¡m°]´I¡n¥@¬É500±jªº¸ó°ê¥ø·~¡A¨ä¤¤¶W¹L75%¬°¥«­È¶W¹L10»õ¬ü¤¸ªº¥ø·~¡C³o¥÷³ø§i¤ÀªR¤F132®a¥¿¦b¦Ò¼{©Î¤w¸g§ïÅܨä¨ÑÀ³Ãì±ÄÁʨӷ½ªº¥ø·~¡A²[»\2018¦~¦Ü2023¦~¡B¦@232­Óªº²£¦a¾E²¾¡C½Õ¬d¼Æ¾ÚÅã¥Ü¡A¤j³¡¤Àªº²£¯à¬y°Êµo¥Í©ó¨È¬w¡G55%¦bªF«n¨È¤Î«n¨È¡B6%¦bªF¥_¨È¡B17%¦b¬ü¬w¡A©|¦³12%¦b¼Ú¬w¡C¥ø·~¾E²¾²£¦a¦ÜªF«n¨È¦a°Ï³Ì¥D­nªº­ì¦]¬O¬°¤FÁקK¹L«×¥õ¿à³æ¤@¥«³õ»s³y¡C

¹Ï¤@¡B2018¦~¦Ü2023¦~¥ø·~·h¾E¤À§G

¹Ï¤ù¨Ó·½¡GKPMG¡m¨È¤Ó¦a°Ï¥þ²y±ÄÁʸѱK¡n³ø§i

¹L¥h¤T¦~¶¡¡A¤¤°êªº¶i¥X¤f¦¨ªø³t«×¬ù¬°¥þ²y¥­§¡ªº¤­­¿¤§¦h¡C§Y¨Ï¦b¥þ²y¬Ò­±Á{¥~¨Óª½±µ§ë¸ê¡]FDI¡^µäÁYªº±¡ªp¤U¡Aªñ¦~¤¤°êªº¥~¨Óª½±µ§ë¸ê¼ö«×¨Ì¤£´î¡AÃÒ©ú¤¤°ê±j¤jªº©Ô°Ê¦]¯À¡]pull factors¡^¡A¤]­¢¨Ï¥ø·~¦b¤¤°ê±µ³sÂX®i¡C

ÀHµÛ¥þ²y´º®ðªº´_µd«P¨Ï»Ý¨D¶q¼W¥[¡A¦U¤j¼t®a¯É¯É¬Û¤¤¨È¬w¨ÑÀ³Ã쥫³õªº¦h¤¸­I´º¡A¨M©w±N²£½u³]¦b¨È¬wªº±¡§Î¤é¯q­Ñ¼W¡C¦À¥@´Ü«ü¥X¡A¾¨ºÞ¨ü¨ì¬Ì±¡¼vÅT¡A¤¤°êªº¶T©ö¥«³õ¦a¦ì¤´µMÃø¥H°Ê·n¡A¯S§O¬O¦b¬ì§Þ²£«~ªº¥«¦û²v³s³sÃk¤É¡A½Ñ¦p¾÷±ñ©M³]³Æ¡B´¼¼z«¬¤â¾÷»Pµ§°O«¬¹q¸£¡A¥H¤Î·s¿³ªººñ¦â¬ì§Þ²£«~µ¥¡C¤£¹L¡A¬Ì±¡»P¦a½t¬Fªv±¡¶Õ±a¨Óªº¦ÒÅç¡A­¢¨Ï¥ø·~­«·s«ä¦Ò¨ä¥þ²y¨ÑÀ³Ã쪺¥¬§½©M¸gÀç®æ§½¡A±q¦ó³B¨ú±o­ìª«®Æ¡B¤D¦Ü¥Í²£½uªº·h¾E¦a³£¬O¸ó°ê¥ø·~¦Ò¶qªº­«ÂI¡C

¦ÓªF«n¨È¬O¨È¬w²Ä¤T¤j¡B¥@¬É²Ä¤­¤jªº¸gÀÙÅé¡A¦¹¨è¥¿¨«¦V»P¤¤°ê¬Û¦üªº¸gÀÙ¦¨ªø¸ô®|¡C¨ä¤¤¡A®È¹C·~¥i»¡¬OªF«n¨È³ÌÁ|¨¬»´­«ªº²£·~¡A¥Ø«e¥¿½wºC¦ýí°·ªº´ÂµÛ¬Ì±¡«e½l³yªº4,000»õ¬ü¤¸¬ö¿ý«e¶i¡A³s±a¥[±j¤F®ø¶OªÌ«H¤ß¡A¨Ã«P¶iªF«n¨È¾ãÅé°Ï°ì¸gÀÙªºÁcºa¡C

¤w¦³¶W¹L¤­¦¨¡]53%¡^ªº¥ø·~¿ï¾Ü±N²£½u¾E²¾¦Ü¨ã³Æ»s³y»P¥Í²£¬ÛÃö°ò¦«Ø³]ªº°ê®a¡C±q²£·~ªº¨¤«×¨Ó¬Ý¡A±q¤¤°ê²¾©¹¨ä¥L°ê®a¶i¦æ¥Í²£ªº²£·~¥H®ø¶O©Ê¹q¤l²£«~¬°¥D¡A¥e35%¡A¦A¨Ó¨Ì§Ç¬O®a¥Î²£«~13%¡B¤u·~¥Î«~12%©M¨T¨®10%¡CµM¦Ó¡A¤´¦³¨ä¥Lªº±À°Ê¦]¯À¡]push factors¡^»P©Ô°Ê¦]¯À¼vÅT¥ø·~²£¦a·h¾Eªº¨Mµ¦¡C®Ú¾Ú²Î­p¡A¸û¬°ÅãµÛªº±À°Ê¦]¯À¥]¬A°ª¦a»ù¡B³Ò°Ê¤O¤£¨¬¡B¬Ì±¡¬ÛÃö¸T¥O¤Î­ìª«®Æµu¯Êµ¥¡A¬ù¥e25%¡F¦Ó©Ô°Ê¦]¯À«h¦³Àu¤Æ¨ÑÀ³Ã쪺«´¾÷¡]7%¡^¡B§ó±µªñ®ø¶O¥«³õ¡]6%¡^¡B§C·Gªº¦a»ù»P³Ò°Ê¤O¡]6%¡^¡A¥H¤Îµ|½áÀu´f¡]5%¡^¡A¦@­p24%¡]¸Ô¨£¹Ï¤G¡^¡C

¹Ï¤G¡B¨ÑÀ³Ã쥫³õ¾E²¾¦¨¦]

¹Ï¤ù¨Ó·½¡GKPMG¡m¨È¤Ó¦a°Ï¥þ²y±ÄÁʸѱK¡n³ø§i

»W¶Õ«Ýµoªº¶V«n

¦Ó¦b¦¹ªi²£¦a¨ÑÀ³Ãì¾E²¾¹Lµ{¤¤¡A¶V«n¬O³Ì¤jªº²£¦a²¾Âà±µ¦¬°ê®a¡]receiving country¡^¡A¤]¬O°ß¤@¦P®É§l¤Þ°ªªþ¥[»ù­È²£·~¡]¹q¤l¡B¤u·~©M¹s²Õ¥ó¡^©M§Cªþ¥[»ù­È²£·~¡]®a©~¡BªA¹¢©M¾c¼i¡^¶i¾nªº¥«³õ¡C¥Ñ©ó¤¤°ê¶É¦Vµo®i§ó¦h³]­p¡B«~µP¤Î¬ãµoµ¥°ªªþ¥[»ù­Èªº¥þ²y©Ê°Ó«~¡AªF«n¨È°ê®a¦]¦Ó¶¶¶Õ±µ¤â¤£¥i©Î¯Êªº°ò¦¥Í²£¤Î²Õ¸Ë§@·~¡C¦À¥@´Ü¤ÀªR¡A¶V«n¾ÌÂÇÀu´fªºµ|²v¤Î¼s³]¤u·~¶é°Ï§l¤Þ¥~¨Ó§ë¸ê¤H¡A¨Ã¦bªF«n¨È¥«³õ¤W²æ¿o¦Ó¥X¡A¥[¤W¸û¤£¨ü¦a½t¬Fªv­·ÀI¼vÅT¡A¥H¤Î§C·Gªº¤g¦a»P³Ò°Ê¤O¡A¤]¬O¶V«n§l¤Þ¥ø·~¤J¥DªºÃöÁä¦]¯À¡C

±q³\¦h¤è­±¨Ó¬Ý¡A¶V«n»P¼sªF«D±`¬Û¦ü¡A¥u¬O¶V«nµo®iµ{«×±ß¤Fªñ¤Q¦~¡C¨Æ¹ê¤W¡A¶V«n2021¦~ªº¤H¼Æ³W¼Ò¡B¤H¤f²Õ¦¨¤Î³Ì§CÁ~¸ê¤ô·Ç¡A¬Ò³ô¤ñ2011¦~ªº¼sªF¡C¦b2022¦~²Ä¤@©u¡A¶V«nªº¥X¤f¶q¤w¶W¶V²`¦`¡A¤ñ¥ý«e¹w¦ôªº®É¶¡§ó´£«e¡AÅã¥Ü¶V«n¥¿¥HÅå¤Hªº³t«×Â૬¸ÀÅÜ¡C¤Q¦~¤§¤º¡A¶V«n¥X¤f¶µ¥Ø±q­ì¥»¥H¹A·~©MªA¹¢¡AÅܦ¨¥H¹q¤l¹s²Õ¥ó¤Î¹q¸£³]³Æ¬°¤j©v¡AÅkµM¦¨¬°¥Í²£¤â¾÷»P³q°T³]³Æªº«e¾W¡A¨Ã¥B¥¿¦b§Ö³t§Î¦¨¤@­Ó¤j«¬ªº¤¤²£¶¥¯Å®ø¶O¥«³õ¡C

¤£¹L¡A¦À¥@´Ü¤]´£¿ô¡A¥x°Ó«e©¹¶V«n§ë¸ê»Ý­n¯S§O¯d·N¡A¶V«n¬°¤F¿í´`¡u¸ó¤Ó¥­¬v¹Ù¦ñ¥þ­±¶i¨B¨ó©w¡v¡]Comprehensive and Progressive Agreement for Trans-Pacific Partnership¡A²ºÙCPTPP¡^¡A2024¦~±N­±Á{Á~¸ê½Õ¤É¾É­P¦¨¥»¤W¤ÉªºÀ£¤O¡CÁöµM¶V«n¦b°ò¦«Ø³]»P³Ò°Ê¤O±j¶´«×ªº­±¦V¤W«ùÄòºë¶i¡A¦ý¦]¾Fªñ¤¤°ê³o­Ó¥@¬É¤u¼t¡A¶V«n¦b§êºt¨È¬w¨ÑÀ³Ã쥫³õ¤è­±¡A¤´±N¨ü¨ì¤@©wµ{«×ªº­­¨î¡C

¨È¬w·s¿³¥«³õµo®i­È±o´Á«Ý

®Ú¾Ú°ê»Ú³f¹ô°òª÷²Õ´¡]IMF¡^ªº³Ì·s¹w´ú¡A¨È¬w·s¿³¥«³õ©Mµo®i¤¤¸gÀÙÅ餵¦~ªº¸gÀÙ¦¨ªø³t«×±N¤ñ¥þ²y¥­§¡¤ô·Ç°ª¥X20%¡A¾¨ºÞªñ´Á¥þ²y¸gÀÙ¤´¨ü¦h¤è¦]¯À¤zÂZ¡A¦ý¨È¤Ó¦a°Ïªº¸gÀÙ¦¨ªø¤´­È±o´Á«Ý¡C¥ø·~¦b·h¾E©ÎÂಾ²£¯à¦Ü¤@­Ó¥þ·sªº°ê®a®É¡AÃöÁä¦Ò¶q¦]¯À¬°¹B¿é¦¨¥»¡B¥æ³f¥i¾a©Ê¡B¨ÑÀ³¤è¶q¯à¤Î¨ÑÀ³°Ó°]°Èí©w©Ê¡A¬°ÂX®i°ê®a¸gÀÙ¡A¬F©²À³«ùÄò¹ê¦æ¦U¶µ¦³®Ä±¹¬I¡BÀu´fµ|²v»P°t®M³W¹º¡A¥H§l¤Þ§ó¦h»s³y°Ó¡B¨ÑÀ³°Ó¡B«~µP°Ó»P§ë¸ê¤Hªºª`¤J¡A¨Ã¬°¥ø·~´M¨D¤H¤~©M³Ò°Ê¤O¡C

¸ê®Æ¨Ó·½¡G

¡m¨È¤Ó¦a°Ï¥þ²y±ÄÁʸѱK¡n¡AKPMG¡A2023/6/13¡C

¡i¥»¤å¥¼§¹¡A§¹¾ã¤º®e½Ð¨£¡m¥_¬ü´¼Åv³ø¡n335´Á¡GªF«n¨È²£¯à±U°_¡G¶V«n±N¦¨¬°¥t¤@­Ó¤¤°ê¼sªF¡H¡j

¡°¦p±ýÂà¸ü¥»¤å¡A½Ð»P¥_¬ü´¼Åv³øÁpµ¸

 
¡m¼Æ¦ìÂ૬±M¿è¡n-2 ¥ø·~¼Æ¦ìÂ૬¸gÅç¤À¨É¡G¸s³Ð¥ú¹q¤Î¤¤¥ú¹q´¼¯àª«¬y
§õ²Q½¬¢¬¥_¬ü´¼Åv³ø¡@½s¿è³¡
¦b¥»¥Z¡m¼Æ¦ìÂ૬±M¿è¡n²Ä1½g¤å³¹¡m§Ú°ê¼Æ¦ìÂ૬³Ì¤jÁô¼~¡G¥xÆW¥ø·~¹ï¼Æ¦ìÄAÂбj«×ªº»{ª¾»·§C©ó¥þ²y¤ô¥­¡n¥i¥Hµo²{¡A¦b­±¹ï¼Æ¦ìÂ૬ªº¬D¾Ô®É¡A¥xÆW²£·~¹ï¼Æ¦ìÄAÂнÄÀ»ªº·P¨üµ{«×»·§C©ó¥þ²y¤ô¥­¡A±q¦Ó¤í¯Ê±À°Ê¤Î°õ¦æªº·NÄ@¡CµM¦Ó¡A¥xÆWªº»s³y·~«o¬O¨Ò¥~¡A±q´¼¼z»s³y¨ìÁÚ¤J¤u·~4.0¡A¥xÆW»s³y·~¤¤ªº¤¤¡B¤j«¬¼t°Ó¤£¶ÈºòÀH¥þ²y¼Æ¦ìÂ૬ªº¸}¨B¡A¦³¨Ç¬Æ¦Ü¤w¶W¶V¡F¨ä¤¤¡A°ª¶¥ºÞ²zªÌ¡]C-suite¡^ªº»{ª¾¡Bµ¦²¤¤Î°Ñ»P°õ¦æ¦ÜÃöºò­n¡C§@¬°¡m±M¿è¡nªº²Ä2½g¤å³¹¡A¥»¤å¤À¨É¤F¥xÆW¤¤¡B¤j«¬¥ø·~ªº¼Æ¦ìÂ૬¸gÅç¡A´Á¥i²£¥Í¥ÀÂû±a¤pÂûªº®ÄÀ³¡A³ê¿ô²£·~¥ÍºAÃ줤¤¤¤p¥ø·~ªºÂ૬·NÃÑ¡C

±q¥ª¦Ü¥k¡G¸s³Ð¥ú¹qªÑ¥÷¦³­­¤½¥qÁ`¸g²zº[Àç¹Bªø·¨¬W²»¡BGoogle Cloud»OÆW·~°È°ÆÁ`¸g²z³¯¦W¼ý¡B²MµØ¤j¾Ç°õ¦æ°Æ®Õªø²ºÕ´IÁ¿®y±Ð±Â¡B¤¤¥ú¹q´¼¯àª«¬yªÑ¥÷¦³­­¤½¥q¸³¨ÆªøªL©v«Û¡B¶Ô·~²³«H­·ÀIºÞ²z¿Ô¸ßªÑ¥÷¦³­­¤½¥q¼Æ¦ìÂ૬ªA°È°õ¦æ°ÆÁ`¸g²z³\±ö§g

Äá¼v¡G§õ²Q½¬

¦]À³ªñ¦~¨Ó´¼¼z»s³y»P¼Æ¦ìÂ૬¦¨¬°¥þ²y»s³y·~«ùÄòÃöª`ªº­«ÂIijÃD¡A¶Ô·~²³«H­·ÀIºÞ²z¿Ô¸ßªÑ¥÷¦³­­¤½¥q©ó6¤ë14¤é»PGoogle Cloud»OÆW¡B°ê¬ì·|¤H¤u´¼¼z»s³y¨t²Î¡]AIMS¡^¬ã¨s¤¤¤ß¦@¦PÁ|¿ì¡m¥ÃÄò»s³yÂŹϡG¥H¬ì§Þ½á¯àªº¶´©Ê¨ÑÀ³Ãì¡n¬ã°Q·|¡C·|¤¤¡A¸s³Ð¥ú¹q¤Î¤¤¥ú¹q´¼¯àª«¬y¥H¥ø·~¨­¥÷¤À¨É¤F¼Æ¦ìÂ૬¸gÅç¡A·¥¨ã°Ñ¦Ò»ù­È¡C

¸s³Ð¥ú¹qÁ`¸g²z·¨¬W²»½Í¥ø·~¼Æ¦ìÂ૬¡G1. §ä¦Ñ®v¡B2. §ä¼Ð¬ñ¡B3. ¨M¤ß³e¹ý

¥Ñ¥@¬É¸gÀٽ׾¡]WEF¡^©Ò±À°Êªº¡u¥þ²y¿O¶ð¤u¼tºô¸ô»{ÃÒ¡v±M®×§@¬°¥þ²y»s³y·~ªº¼Ð¬ñ¡A¥Ø«e§Y¬ù¦³120®y¼Ð¬ñ¤u¼t¤J¦C¡C¸s³Ð¥ú¹q§@¬°¥þ²y»â¥ýªºÅã¥Ü¬ì§Þ¤j¼t¡A¤@ª½­P¤O©ó±À°Ê¼Æ¦ìÂ૬©M¥ÃÄòµo®i¡A¨Ã¦b2021¦~¦¨¬°¥xÆW²Ä¤@®aÀò±oWEF¡u¿O¶ð¤u¼t¡v»{ÃÒªº­±ªO¼t¡C¸s³Ð¦b2021¦~ªk»¡·|ªºÂ²³ø¤¤¡A§Y¦³¤@­Ó³æ¤¸±j½Õ¡uÂù­yÂ૬ ¡V ¼Æ¦ì¤Æ¨Mµ¦¡v¡]¹Ï1¡^¡C

¹Ï1. ¸s³Ð¥ú¹q±j½Õ¡uÂù­yÂ૬ ¡V ¼Æ¦ì¤Æ¨Mµ¦¡v

¹Ï¤ù¨Ó·½¡G¸s³Ð¥ú¹q2021¦~¤U¥b¦~ªk¤H»¡©ú·|²³ø¡A2021¦~8¤ë6¤é

¦b2022¦~¡A¸s³Ð¶i¤@¨BÂX¤j¤F¼Æ¦ìÂ૬ªº½dÃ¥©M²`«×¡A±j½Õ²£«~³]­p¥Í©R¶g´Á©M²£«~¥æ¥I¥Í©R¶g´ÁªºÀu¤Æ¡A¥þ­±²[»\ºÝ¨ìºÝ»ù­ÈÃì¡A¹ê²{ºñ¦â³]­p¡B§CºÒ¥Í²£©M§CºÒª«¬y¡F¤]±N©ó¤µ¡]2023¡^¦~§¹¦¨¬[³]ESG¼Æ¦rºÞ²z¥­»O¡A¥Ñ¦Û¨­Àu¶Õ§ä¥X²b¹sªº³Ì¨Î¸Ñ¨M¤è®×¡A½T«O¤½¥q¥ÃÄò¤è¦V²Å¦XÁͶաA¨Ã©Ó¿Õ¥[¤JSBTi´îºÒ¥Ø¼Ð­pµe¡A¨î©w´îºÒ¸ô®|¡A¤Þ»â¨ÑÀ³ÃìÃöÁä¨ÑÀ³°Ó¦@¦P´îºÒ¡A¶i¦Ó±NESGµ¦²¤»P·~°È¹BÀç¬Ûµ²¦X´£¤Éºî®Ä¡C

·í³Q°Ý¨ì¡uÁÚ¦V´¼¼z¤u¼t¡A©Î¬O¦b¥´³y¥ø·~¶´©Êªº¹Lµ{¤¤¡A³Ì¤jªº¬D¾Ô¬O¤°»ò¡H¡v®É¡A¸s³Ð¥ú¹qÁ`¸g²zº[Àç¹Bªø·¨¬W²»ªí¥Ü¡A¦b¼Æ¦ìÂ૬ªº¹Lµ{¤¤¡A»Ý­n¦³¡u¦Ñ®v¡v¡AÁöµM­è¶}©l³£¦bºN¯Á¡A¦ý¬O¤j¤è¦V¤@©w­n¹ï¡A©Ò¥H·¨¬W²»²Ä¤@¥ó¨Æ´N¬O§ä±M®a¡B²Ä¤G­Ó¥ó¨Æ´N¬O§ä¼Ð¬ñ¡A¥h«ä¦Ò´N§O¤H°µ±o¨ìªº¡A§Ú­Ì­n«ç»ò°µ¡H

¹³ÂE®ü¬O¸s³ÐªºªÑªF¡A©ó¬O«K¥h°ÝÂE®ü¥L­Ì¦b¼Æ¦ìÂ૬¤è­±ªº¸gÅç¡F±µµÛ¸s³Ð¦A§ä¥L­Ìªº«È¤á½Ð±Ð¡A¦Ó¸s³Ðªº«È¤á¼w°ê¦èªù¤l¬°¥þ²y¤u·~4.0ªº»â¥ýªÌ¡A«K¦¨¬°¤F³Ì¦nªº½Ð±Ð¹ï¹³¡C¦³¤@¦¸»P¦èªù¤l¶}·|¡A¦b²³ø¤Î°Q½×µ²§ô«á¡A¦èªù¤lªº¥Nªí¶]¹L¨Ó©M·¨¬W²»»¡¡G¡u§Ú­Ì¥H¬°¤u·~4.0¬O§Ú­Ì¼w°ê¤H¤é¦Õ°ÒªºÅº¶Æ¡A²{¦b¤~µo²{­ì¨Ó¦b§A­Ì»OÆW¸¨¹ê±o«Ü¦n¡C¡v³o¹ï¸s³Ð¨Ó»¡¡A¬O¬Û·í¥¿­±ªºªÖ©w¡C

·¨¬W²»¦^¾Ð¦bÂ૬ªì´Á¡A¥Ñ©ó¥xÆW¤ñ¸ûµ½ªøµwÅé¡A¤]´N¬O¸U¾÷Ápºôªº·§©À¡A¦­´Á±j½Õªº¬O´¼¼z»s³y¡CµM¦Ó¡A·¨¬W²»·NÃѨì¦pªG¤£¶i¦æ¼Æ¦ìÂ૬¡A¥ø·~¥i¯à¨S¿ìªk¦b¥¼¨ÓÄvª§¤¤¬¡¤U¥h¡A¦]¦¹¸s³Ð¦b¶i¦æ¼Æ¦ìÂ૬®É¡A¤£¬O¥Ñ¸ê°Tªø»â¾É¡B¤]¤£¬O¥Ñ»s³yªø»â¾É¡A¦Ó¬O¥ÑÁ`¸g²z¥»¤H¿Ë¦Û»â­x¡C·í®É¦¨¥ß±À°Ê¤p²Õ¡A¤@­Ó¤@­Ó¥hºÞ¡B¥h¨n¡F¤]°ß¦³³o¼Ëªº·þ¾É¤~¯àÅý¥ø·~©¹«e±À¶i¡C·¨¬W²»ªí¥Ü¡A¦]¬°¯A¤Î¬yµ{ªº§ïÅÜ¡A¦]¦¹»â­xªº¤H¥²¶·¬O¹ï¤½¥q·~°È³Ì¼ô±xªº¡Aª¾¹D¤½¥q¨º¸Ì¦³°ÝÃD¡A¤£¯àÀH«K«ü¬£¤@­Ó³¡Äݨӭt³d¡C

³Ì«á¡A·¨¬W²»±j½ÕÅý¦Û¤v¦³«H¤ß¤]«Ü­«­n¡C¥Hª¦¤s¬°¨Ò¡A¥ý±q²³æ°ò¦ªº¶}©l¡AºCºC¦A§âÃø«×´£¤É¡A³Ì«á¤~¬D¾Ô¥É¤s¡A³o¼Ë¤l¾ã­Ó¹Î¶¤ªº¤h®ð«K·|©Ô¤W¨Ó¡C

¤¤¥ú¹q´¼¯àª«¬y¸³¨ÆªøªL©v«Û¡G¸êª÷©M¤H¤~¬O¤¤¤p¸ê·~­±¹ï¼Æ¦ìÂ૬®Éªº³Ì¤jµhÂI

¤¤¥ú¹q´¼¯àª«¬yªÑ¥÷¦³­­¤½¥q¸³¨ÆªøªL©v«Û«ü¥X¡A´¼¼z¤u¼t³z¹Lª«¬y¸Ñ¨M¤è®×©MAI§Þ³N¤§À³¥Î¡A´£°ª¥Í²£®Ä²v¡BÀu¤Æ¸ê·½§Q¥Î©M¹ê²{¥ÃÄòµo®i¡C¦Û¥D¾É¯è¾÷¾¹¤H¡]AMR¡^¥D­nÀ³¥Î©ó¦Û°Ê·h¹B¡AÀô¹ÒºÊ´ú¨t²Î³¡¸p©MµL¹Ð«Ç¡AÂǥѥý¶iªº¨t²Î¤Æ¾É¯è©M¦Û¥D¨Mµ¦¥\¯à¡A´£°ª·h¹B®Ä²v¡A´î¤ÖºÒ±Æ©ñ¡A´£¤É¤u§@®Ä²v¨Ã¹F¦¨Àô¹Ò¤Í¦n¤§¥Ø¼Ð¡C¥t¤@¤è­±¡A³z¹LÀô¹ÒºÊ´ú¨t²Î¡Aµ²¦Xª«Ápºô¡]IoT¡^§Þ³N©MAI¤ÀªR¡A¥i§Y®ÉºÊ´ú¥Í²£Àô¹Òªº·Å«×¡BÀã«×©M®ðÅé±Æ©ñµ¥¦]¯À¡A´£°ª¦w¥þ©Ê¡B¥i¾a«×©M¨}²v¡F¦bµL¹Ð«Ç¤¤«h¹ê²{ºë½T±±¨î©M§Y®ÉºÊ´ú¡A´£°ª²£«~«~½è©M¥Í²£®Ä²v¡C´¼¼z¤u¼tª«¬y¸Ñ¨M¤è®×¥i´£¨Ñ¥þ­±ªº¥Í²£¡B¾P°â©M¨ÑÀ³Ãì¤ÀªR¸ê®Æ¡A¥H¨ó§U¸gÀ綥¼h¨î­q§ó¦³®Äªº·~°Èµ¦²¤»PÀç¹B¤è°w¡C

·í³Q°Ý¤Î¤¤¤p¥ø·~¦b¼Æ¦ìÂ૬¤¤¹J¨ìªºµhÂI¤Î¬D¾Ô®É¡AªL©v«Ûªí¥Ü¡A½Í¨ì¼Æ¦ìÂ૬¤j®a³£·Q°µ¡A¦]¬°¤j®a³£¬Ý¨ì¦¨ªG¡A¥i¬O¡A¦b½Í¨ì§ë¸êªº®É­Ô¡A¤j·§¦³¤@¥b¥H¤W³£·|«o¨B¡C³Ì¥D­n¦³2­Ó­ì¦]¡A¤@­Ó¬O§ë¸êª÷ÃB¡A¥t¤@­Ó­ì¦]«h¬O¦b¹ê»Ú¾Þ§@¤W¨S¦³¨º»ò¦hIT¡]¸ê°T§Þ³N¡^¤H­û¡A¨S¦³¨º»ò¦h¦Û°Ê¤Æ¤uµ{®v¨Ó³B²z¦Û°Ê¤Æªº¤u¨ã¡C¦]¦¹¥²¶·­n´£¨Ñ¤@­Ó¤ñ¸ûºò±Kªº¸Ñ¨M®×µ¹³o¨Ç¤¤¤p¥ø·~¡A¤]´N¬O»¡§â¸Ñ¨M¤è®×¥´¥]¡A¥]¸Ë¦¨¤@­Ó²³æªº¸Ñ¨M¤è®×¡AÅý¼t°Ó¥´¶}¡B¦w¸Ë«á¡A§Y¥i§Ö³t¨Ï¥Î¡C¦ý¥²¶·ª`·Nªº¬O¡A³W«h³]©w¤§«á§Y¤£¯àÀH·N§ïÅÜ¡A´N¦p¦P©Ò¦³¦Û°Ê¤Æ³]¬I¤@¯ë¡A¦pªGÀH¤ß©Ò±ýªº§ïÅÜ¡A¨º§Y«K¬OAI¤]¬OµL¸Ñ¡C¦¹¥~¡A¦b´À¤¤¤p¥ø·~¥´³y¦Û°Ê¤Æ¤è®×®É¡A­A¾¨¶q§Q¥Î²{¦³³]³Æ¡A¤£©y¦bªì´Á§Y¤j¶q§ë¤J¦b§ï³y©Î«Ø³]·s¨t²Î¡C

¡i§¹¾ã¤º®e½Ð¨£¡m¥_¬ü´¼Åv³ø¡n335´Á¡G¡m¼Æ¦ìÂ૬±M¿è¡n-2 ¥ø·~¼Æ¦ìÂ૬¸gÅç¤À¨É¡G¸s³Ð¥ú¹q¤Î¤¤¥ú¹q´¼¯àª«¬y¡j

¡°¦p±ýÂà¸ü¥»¤å¡A½Ð»P¥_¬ü´¼Åv³øÁpµ¸

©µ¦ù¾\Ū¡G

¡m¼Æ¦ìÂ૬±M¿è¡n-1 §Ú°ê¼Æ¦ìÂ૬³Ì¤jÁô¼~¡G¥xÆW¥ø·~¹ï¼Æ¦ìÄAÂбj«×ªº»{ª¾»·§C©ó¥þ²y¤ô¥­

¡m¼Æ¦ìÂ૬±M¿è¡n-3 ¶Ô·~²³«H°õ¦æ°ÆÁ`³\±ö§g½Í¥ø·~¼Æ¦ìÂ૬3¤j¬D¾Ô

 
¡mIP¤pÃã¨å¡n±M§QÅv½èÅv
§dºÑ®Z¢¬¥_¬ü´¼Åv³ø¡@½s¿è³¡
±M§QÅv¬O°]²£Åvªº¤@ºØ¡A¥i¥H®³¨Ó³]©w½èÅv¡A¤]´N¬O±M§QÅv¤H°µ¬°¶Å°È¤H¡A¬°¨Ï¨ä¶ÅÅv¤Hªº¶ÅÅv¯àÀò±o¾á«O¡A¦Ó±N±M§QÅv³]©wÅv§Q½èÅv¡A±N¨Ó¶ÅÅv¤H´N¸Ó±M§QÅv¦³Àu¥ý¨üÀvªºÅv§Q¡C­Y­n±N±M§QÅv³]©w½èÅv¡A¥²¶·¦V¸gÀÙ³¡´¼¼z°]²£§½¿ì²zµn°O¡A¤~¯à¹ï§Ü²Ä¤T¤H¡A¦¹§Y¡u±M§QÅv½èÅv³]©wµn°O¡v¡F¦Ó·í½èÅv³]©w­ì¦]®ø·À®É¡A«h¥i¿ì²z¡u±M§QÅv½èÅv¶î¾Pµn°O¡v¡C

®Ú¾Ú¡m¥Áªk¡n²Ä900±ø[1]³W©w¡A¡uÅv§Q½èÅv¡v«üªº¬O¡u¥iÅý»P¤§¶ÅÅv©Î¨ä¥LÅv§Q¬°¼Ðªºª«¤§½èÅv¡v¡A¦]¦¹Åv§Q½èÅv¤§¼Ðªºª«¡A¥²¶·¬°¥iÅý»Pªº°]²£Åv¡A±M§QÅv§YÄÝ©ó¥i¥HÅv§Q½èÅvªº¨ä¤¤¤@ºØ¼Ðªºª«¡C

·í±M§QÅv¬°¦@¦³®É¡A°£«´¬ù¥t¦³¬ù©w¥~¡A«D¸g¦@¦³¤H¥þÅé¦P·N¡A¤£±o³]©w½èÅv¡C±M§QÅv¤§¦@¦³¤H«D¸g¨ä¥L¦@¦³¤H¤§¦P·N¡A¥ç¤£±o¥H¨äÀ³¦³³¡¤À³]©w½èÅv¡C­Y¥H±M§QÅv¬°¼Ðªº³]©w½èÅv¡A°£«´¬ù¥t¦³¬ù©w¥~¡A½èÅv¤H¤£±o¹ê¬I¸Ó±M§QÅv¡C

±M§QÅv½èÅv³]©wµn°O

¥Ó½Ð±M§QÅv½èÅvµn°O¡A±o¥Ñ½èÅv¤H¡]«ü¥e¦³½èª«ªº¶ÅÅv¤H¡^©Î¥X½è¤H¡]±N½èª«¥æµ¹½èÅv¤H¡A¨Ñ§@¸Ó¶ÅÅv¾á«Oªº¤H¡^³æ¤è´£¥X¥Ó½Ð¡C¥Ó½Ð±M§QÅv½èÅv³]©wµn°OªÌ¡AÀ³¥Ñ±M§QÅv¤H©Î½èÅv¤H³Æ§´¥Ó½Ð®Ñ¤Î±M§QÃҮѡB³W¶O¡A¨ÃÀ˪þ¤U¦C¤å¥ó¡G

1.¥Ó½Ð½èÅv³]©wµn°O¡G½èÅv³]©w«´¬ù©ÎÃÒ©ú¤å¥ó1¥÷¡C

2.¥Ó½Ð½èÅvÅܧóµn°O¡GÅܧóÃÒ©ú¤å¥ó1¥÷¡C

3.¥Ó½Ð½èÅv¶î¾Pµn°O¡G¶ÅÅv²MÀvÃÒ©ú¤å¥ó¡B½èÅv¤H¦P·N¶î¾P½èÅv³]©w¤§ÃÒ©ú¤å¥ó¡Bªk°|§P¨M®Ñ¤Î§P¨M½T©wÃÒ©ú®Ñ©Î¨Ìªk»Pªk°|½T©w§P¨M¦³¦P¤@®Ä¤O¤§ÃÒ©ú¤å¥ó1¥÷¡C

±M§QÅv½èÅv³]©w¤§¦¬¶O¼Ð·Ç

¥Ó½Ð±M§QÅv½èÅv³]©wµn°O¡A¨C¥ó¥Ó½Ð¶O¬°·s¥x¹ô¤G¤d¤¸¡F¥Ó½Ð±M§QÅv½èÅv®ø·Àµn°O¡A¨C¥ó·s¥x¹ô¤G¤d¤¸[2]¡C¥Ó½Ð±M§QÅv½èÅv¤§¨ä¥LÅܧó¨Æ¶µ¡A¨C¥ó¥Ó½Ð¶O¬°·s¥x¹ô¤T¦Ê¤¸[3]¡C

¦b³]©w±M§QÅv½èÅvµn°O®É¡A­Y¬°­l¥Í³]­p±M§Q¡BÁp¦X·s¦¡¼Ë±M§Q¡A¶·»P¥À®×¤@¨Ö¿ì²z½èÅvµn°O¡C­l¥Í³]­p±M§Q®×À³³v®×¿ì²z½èÅvµn°O¡A¨ÃÀË°e¥Ó½Ð®Ñ¡B½èÅv³]©w«´¬ù©ÎÃÒ©ú¤å¥ó1¥÷¤Î½èÅvµn°O³W¶O¡FÁp¦X·s¦¡¼Ë±M§Q®×¦P¼Ë¤]­n³v®×¿ì²z½èÅvµn°O¡A¨ÃÀË°e¥Ó½Ð®Ñ¡B½èÅv³]©w«´¬ù©ÎÃÒ©ú¤å¥ó1¥÷¡A¦ýµL¶·¥t¥~ú¯Ç½èÅvµn°O³W¶O¡C

±M§QÅv½èÅv¶î¾Pµn°O

­Y¦]½èÅv³]©w­ì¦]®ø·À¡A±ý¿ì²z½èÅv¶î¾Pµn°OªÌ¡AÀ³¥Ñ±M§QÅv¤H©Î½èÅv¤H¡A³Æ¨ã¥Ó½Ð®Ñ¡B³W¶O¡B¶ÅÅv²MÀvÃÒ©ú¤å¥ó¡A©Î½èÅv¤H¦P·N¶î¾P½èÅv³]©w¤§ÃÒ©ú¤å¥ó¡A©Îªk°|§P¨M®Ñ¤Î§P¨M½T©wÃÒ©ú®Ñ©Î¨Ìªk»Pªk°|½T©w§P¨M¦³¦P¤@®Ä¤O¤§ÃÒ©ú¤å¥ó¡A§Y¥i¿ì²z¶î¾Pµn°O¡C

¡i§¹¾ã¤º®e½Ð¨£¡m¥_¬ü´¼Åv³ø¡n335´Á¡G¡mIP¤pÃã¨å¡n±M§QÅv½èÅv¡j

¡°¦p±ýÂà¸ü¥»¤å¡A½Ð»P¥_¬ü´¼Åv³øÁpµ¸

©µ¦ù¾\Ū¡G¡mIP¤pÃã¨å¡n°Ó¼Ð½èÅv

¸ê®Æ¨Ó·½¡G

1.´¼¼z°]²£§½¡G¦ó¿×±M§QÅv½èÅvµn°O¡HÀ³¦p¦ó¿ì²z¡H¡]2022/12/26§ó·s¡^

2.´¼¼z°]²£§½¡G±M§QÅv½èÅvµn°O¥Ó½Ð®Ñ¥Ó½Ð¶·ª¾¡C

³Æµù¡G

1.¥Áªk²Ä900±ø¡C

±M2.§Q³W¶O¦¬¶O¿ìªk²Ä7±ø¡C

±M§Q³W¶O¦¬¶O¿ìªk²Ä8±ø¡C

 
 
¥»¹q¤l³øµÛ§@Åv§¡ÄÝ¡uÁp¦X½u¤W¤½¥q¡v©Î±ÂÅv¡uÁp¦X½u¤W¤½¥q¡v¨Ï¥Î¤§¦XªkÅv§Q¤H©Ò¦³¡A
¸T¤î¥¼¸g±ÂÅvÂà¸ü©Î¸`¿ý¡C­Y¹ï¹q¤l³ø¤º®e¦³¥ô¦óºÃ°Ý©Î­n¨DÂà¸ü±ÂÅv¡A½Ð¡i
Ápµ¸§Ú­Ì¡j¡C
  §K¶O¹q¤l³ø | µÛ§@ÅvÁn©ú | Áô¨pÅvÁn©ú | Ápµ¸§Ú­Ì